TrovaGene (TROV) Receives a Buy from Noble Financial

By Ryan Adsit

Noble Financial analyst Ahu Demir maintained a Buy rating on TrovaGene (TROVResearch Report) yesterday and set a price target of $23.00. The company’s shares closed last Monday at $1.34, close to its 52-week low of $1.21.

According to, Demir is a 2-star analyst with an average return of 1.2% and a 41.7% success rate. Demir covers the Healthcare sector, focusing on stocks such as Onconova Therapeutics, Dyadic International, and Electrocore Llc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TrovaGene with a $14.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.65 and a one-year low of $1.21. Currently, TrovaGene has an average volume of 415.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ZYQC Group Holding Ltd. engages in the acquisition, exploration, and development of natural resource properties. The company was founded on September 16, 2009 and is headquartered in Reno, NV.